Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US

References

• Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the Unites States and evidence of an increasing trend in women. Neurology 2002;59:136-8
   Web of Science ®Google Scholar
• National Multiple Sclerosis Society. “Who gets MS?”. http://www.nationalmssociety.org/index.aspx. Accessed January 27, 2012
   Google Scholar
• Noonan CW, Williamson DM, Henry JP, et al. The prevalence of multiple sclerosis in 3 US communities. Prev Chronic Dis 2010;7:A12. http://www.cdc.gov/pcd/issues/2010/jan/08_0241.htm. Accessed January 27, 2012
   Google Scholar
• Pope GC, Urato CJ, Kulas ED, et al. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology 2002;58:37-43
   PubMed Web of Science ®Google Scholar
• Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 2002;8:469-76
   PubMedGoogle Scholar
• Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52
   PubMed Web of Science ®Google Scholar
• Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm. 2009;15:543-55
   PubMed Web of Science ®Google Scholar
• Bourdette DN, Prochazka AV, Mitchell W, et al. VA Multiple Sclerosis Rehabilitation Study Group. Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. Arch Phys Med Rehabil 1993;74:26-31
   PubMed Web of Science ®Google Scholar
• Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-25
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006;66:1696-702
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Birnbaum HG, Samuels S, et al. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US. Pharmacoeconomics 2009;27:681-91
   PubMed Web of Science ®Google Scholar
• National Multiple Sclerosis Society. What is MS? http://www.nationalmssociety.org/about–multiple–sclerosis/what–we–know–about–ms/what–is–ms/index.aspx. Accessed February 1, 2012
   Google Scholar
• National Multiple Sclerosis Society. The MS Disease-Modifying Medications General Information. http://www.nationalmssociety.org/about–multiple–sclerosis/what–we–know–about–ms/treatments/index.aspx. Accessed February 1, 2012
   Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000;6:255-66
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997;49:358-63
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised doubleblind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-36
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85
   PubMed Web of Science ®Google Scholar
• Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther 2007;29:2031-48
   PubMed Web of Science ®Google Scholar
• Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Birnbaum HG, Ivanova JI, Samuels S, et al. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs. Curr Med Res Opin 2009;25:869-77
   PubMed Web of Science ®Google Scholar
• Okuda DT, Kozma CM, Dickson M, et al. Relationship between gaps in drug treatment for multiple sclerosis and incidence of exacerbations: findings from a national managed care database. Poster presented and the International Society for PharmacoEconomics and Outcomes Research 13th Annual International Meeting, Toronto, ON, May 3–7, 2008
   Google Scholar
• Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28:51-61
   PubMed Web of Science ®Google Scholar
• Steinberg SC, Faris RJ, Chang CF, et al. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 2010;30:89-100
   PubMed Web of Science ®Google Scholar
• Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-16
   PubMed Web of Science ®Google Scholar
• Erickson SR, Coombs JH, Kirking DM, et al. Compliance from self-reported versus pharmacy claims data with metered-dose inhalers. Ann Pharmacother 2001;35:997-1003
   PubMed Web of Science ®Google Scholar
• Pharmacy Quality Alliance. PQA Approved Measures. http://www.pqaalliance.org/files/PQA%20approved%20measures.pdf. Accessed June 28, 2010
   Google Scholar
• Bureau of Labor Statistics. Consumer Price Index - All Urban Consumers CUSR0000SAM Seasonally Adjusted U.S. City Average Medical Care. http://data.bls.gov/pdq/SurveyOutputServlet;jsessionid=AAC19B5A8C853682CCB5F8CC770065FB.tc_instance4. Accessed February 1, 2012
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Romano PS, Roos LL, Jollis J. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol 1993;46:1075-9
   PubMed Web of Science ®Google Scholar
• National Multiple Sclerosis Society. Symptoms. http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/symptoms/index.aspx. Accessed February 1, 2012
   Google Scholar
• National Multiple Sclerosis Society. Medications Used in MS. http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/treatments/medications/index.aspx. Accessed February 1, 2012
   Google Scholar
• Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ 1999;18:153-71
   PubMed Web of Science ®Google Scholar
• Blough DK, Ramsey SD. Using generalized linear models to assess medical care costs. Health Serv Outcomes Res Method 2000;1:185-202
   Google Scholar
• Brandes DW, Callender T, Lathi E, et al. A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events. Curr Med Res Opin 2009;25:77-92
   PubMed Web of Science ®Google Scholar
• Reynolds MW, Stephen R, Seaman C, et al. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin 2010;26:663-74
   PubMed Web of Science ®Google Scholar
• Tremlett HL, Oger J. Interrupted therapy. Stopping and switching of the β-interferons prescribed for MS. Neurology 2003;61:551-4
   PubMed Web of Science ®Google Scholar
• Holland N, Wiesel P, Cavallo P, et al. Adherence to disease-modifying therapy in multiple sclerosis: Part I. Rehab Nurs 2001;26:172-6
   PubMedGoogle Scholar
• Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009;256:568-76
   PubMed Web of Science ®Google Scholar